Last update June 29, 2020

Adefovir Dipivoxil

High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Adefovir is a nucleotide reverse transcriptase inhibitor, structurally related to adenine, used for treatment of chronic hepatitis B. Usually a long-term treatment is required.
Oral administration once a day.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (not very high molecular weight and low protein binding) makes transfer to milk possible in amounts that could be significant. its use during breastfeding is not recommended (Mahadevan 2006).

There is widespread agreement among medical associations and expert consensus that maternal hepatitis B is not transmitted to the infant through breastmilk and therefore does not contraindicate breastfeeding (Mammas 2017,Visvanathan 2016, Dionne 2016, Fouquet 2016, Sogni 2015).


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Adefovir Dipivoxil in other languages or writings:

Group

Adefovir Dipivoxil belongs to this group or family:

Tradenames

Main tradenames from several countries containing Adefovir Dipivoxil in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 59 %
Molecular weight 502 daltons
Protein Binding < 4 %
VD 0.4 l/Kg
Tmax 0.6 - 4 hours
7 - 11 hours

References

  1. Hale TW. Medications & Mothers' Milk. 1991- . Springer Publishing Company. Available from https://www.halesmeds.com Consulted on April 10, 2024 Full text (link to original source)
  2. Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J. Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut. 2016 Feb;65(2):340-50. Abstract
  3. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits

5,127

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM